An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy.

NCT00210834 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

310

Enrollment

INDUSTRY

Sponsor class

Conditions

Anemia

Interventions

DRUG: epoetin alfa

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Collaborators

[object Object]